Back to all papers

Predicting Chemotherapy Response from Staging Laparoscopy Images

June 24, 2026medrxiv logopreprint

Authors

Schnelldorfer, T.,Castro, J.,Goldar-Najafi, A.,Nugent, F. W.,Gaikwad, B.

Affiliations (1)

  • Tufts Medical Center

Abstract

BackgroundFor patients with metastatic gastrointestinal cancers, chemotherapy resistance is a common phenomenon that, if known in advance, would allow for individualized treatment decisions. This study aimed to test the feasibility of developing a deep learning computer vision system that uses laparoscopy images depicting peritoneal surface metastases (i.e., capturing the in-vivo optical appearance of metastases as a summary of their molecular makeup) to predict whether a patient is resistant to standard chemotherapy. MethodsThe retrospective observational feasibility study included 35 adult patients who underwent staging laparoscopy for non-colon gastrointestinal adenocarcinoma with biopsy-confirmed peritoneal surface metastases and who underwent chemotherapy as their only treatment modality. Chemotherapy resistance was determined based on each patients observed cancer-specific survival after controlling for confounders. ResultsOf 35 patients, 17 were assigned to the chemotherapy sensitive group and 18 to the chemotherapy resistant group. The study cohort provided 1010 laparoscopy image patches of 101 biopsy-confirmed metastases. A densely connected convolutional neural network with cross-validation provided the best results for correctly predicting chemotherapy resistance at the patient level (accuracy 0.80 (95%CI 0.63-0.92), sensitivity 0.72, specificity 0.88, AUC-ROC 0.78). Saliency maps demonstrated the systems trustworthiness. ConclusionIn this study, a prototype surgical computer vision system designed to determine chemotherapy resistance from operative images of peritoneal surface metastases demonstrated its technical feasibility. Further development and validation in a multi-institutional clinical study are pending.

Topics

oncology

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.